Mark is a consultant haematologist who holds a dual appointment with The Kirby Institute for Infection and Immunity and St Vincent's Hospital Sydney. Mark's clinical and scientific interests lie at the intersection of immunity and malignancy, in particular viral malignancies and malignancies occurring in people with HIV and other acquired immunodeficiencies.He is an NHMRC Australian Clinical Research Fellow and the Cancer Institute NSW Future Research Leader Fellow. Mark leads the joint Kirby-St Vincent's clinical research program in cancer and immunodeficiency, which is unique in the Asia Pacific. He established and is the principal investigator for the Australian site of the NIH National Cancer Institute AIDS Malignancy Consortium, their only core site outside the United States. The goals of his reseach program are to develop novel therapies to improve outcomes for people with HIV and cancer, and to use this unique population to help answer fundamental questions about oncogenesis and HIV pathogenesis.